News

Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This…
Read More...

AbCellera announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell…
Read More...

SK Biopharmaceuticals and Arvelle Therapeutics GmbH announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe.…
Read More...

Mayne Pharma Group Limited announced the launch of LEXETTE (halobetasol propionate) Foam 0.05% in the United States. LEXETTE, the conditionally-acceptable trade name for halobetasol…
Read More...

Abilita Bio, Inc. announced that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement,…
Read More...

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting…
Read More...

Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, announced a $68.5 million Series A…
Read More...

Jubilant Biosys announced a new integrated drug discovery collaboration with Sanofi in the CNS therapeutic area. The first collaboration with Sanofi started in 2016, to discover and…
Read More...

Amyris, Inc. and IDRI (Infectious Disease Research Institute) announced IDRI’s receipt of a $4.4 million, five-year grant from the National Institute of Allergy and Infectious Diseases…
Read More...

SGS announced that it will commence its first Malaria Volunteer Infection Study (VIS) in Belgium in February 2019 on behalf of Medicines for Malaria Venture (MMV), a product development…
Read More...

Regeneron Pharmaceuticals and Sanofi announced that Praluent (alirocumab) will be made available at a new reduced U.S. list price of $5,850annually, a 60% reduction from the original…
Read More...

The Epilepsy Society and UCB, a global biopharmaceutical company headquartered in Belgium, with a significant UK R&D hub in Slough, UK, have announced an exciting new collaboration…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and…
Read More...

RegeneRx Biopharmaceuticals announced that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, has executed an agreement with Ora, Inc., located in Andover, Massachusetts,…
Read More...

Eton Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing and supply agreement with Sintetica SA, a Swiss-based pharmaceutical company, to obtain U.S.…
Read More...

WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200. Per the…
Read More...

3SBio Inc. and Verseau Therapeutics, Inc. announced a partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of…
Read More...

Moberg Pharma AB has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50…
Read More...

GlaxoSmithKline plc and Merck KGaA, Darmstadt, Germany announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa).…
Read More...

Xencor announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics,…
Read More...